Finch has a longstanding collaboration with OpenBiome, the first public stool bank. Founded with the mission of providing safe access to fecal microbiota transplantation, OpenBiome provides life-changing treatments to thousands of patients each year. Having built extensive expertise and infrastructure in this field, OpenBiome has supported Finch’s development of CP101, our investigational drug for recurrent C. difficile, which is currently enrolling in a Phase II clinical trial. Through our contractual collaboration, Finch and OpenBiome are working together to fulfill our shared goal of providing patients with access to revolutionary microbial therapies and advancing research in this exciting field.
To find out more about this collaboration, please visit www.openbiome.org/finch-collaboration.